Sulfadoxine Resistance in Plasmodium vivax Is Associated with a Specific Amino Acid in Dihydropteroate Synthase at the Putative Sulfadoxine-Binding Site

Antimicrobial Agents and Chemotherapy - Tập 48 Số 6 - Trang 2214-2222 - 2004
Michael Korsinczky1,2, Ayşegül Taylan Özkan3, Nanhua Chen1, Joanne Baker1, Jetsumon Sattabongkot1, Qin Cheng1
1Department of Drug Resistance and Diagnostics, Australian Army Malaria Institute, Gallipoli Barracks, Enoggera, Qld 4051
2Institute for Molecular Bioscience, University of Queensland, St. Lucia, Qld 4067
3Malaria and Scabies Group, The Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Qld 4029, Australia

Tóm tắt

ABSTRACT Sulfadoxine is predominantly used in combination with pyrimethamine, commonly known as Fansidar, for the treatment of Plasmodium falciparum . This combination is usually less effective against Plasmodium vivax , probably due to the innate refractoriness of parasites to the sulfadoxine component. To investigate this mechanism of resistance by P. vivax to sulfadoxine, we cloned and sequenced the P. vivax dhps ( pvdhps ) gene. The protein sequence was determined, and three-dimensional homology models of dihydropteroate synthase (DHPS) from P. vivax as well as P. falciparum were created. The docking of sulfadoxine to the two DHPS models allowed us to compare contact residues in the putative sulfadoxine-binding site in both species. The predicted sulfadoxine-binding sites between the species differ by one residue, V585 in P. vivax , equivalent to A613 in P. falciparum . V585 in P. vivax is predicted by energy minimization to cause a reduction in binding of sulfadoxine to DHPS in P. vivax compared to P. falciparum . Sequencing dhps genes from a limited set of geographically different P. vivax isolates revealed that V585 was present in all of the samples, suggesting that V585 may be responsible for innate resistance of P. vivax to sulfadoxine. Additionally, amino acid mutations were observed in some P. vivax isolates in positions known to cause resistance in P. falciparum , suggesting that, as in P. falciparum , these mutations are responsible for acquired increases in resistance of P. vivax to sulfadoxine.

Từ khóa


Tài liệu tham khảo

10.1038/nsb0697-490

10.1006/jmbi.2000.4094

Bartelloni, P. J., T. W. Sheehy, and W. D. Tigertt. 1967. Combined therapy for chloroquine-resistant, Plasmodium falciparum infection. Concurrent use of long-acting sulphormethoxine and pyrimethamine. JAMA199:173-177.

10.1016/S0001-706X(02)00264-4

Camargo, A. A., K. Fischer, and M. Lanzer. 1997. Construction and rapid screening of a representative yeast artificial chromosome library from the Plasmodium falciparum strain Dd2. Parasitol. Res.83:87-89.

Camargo, A. A., K. Fischer, M. Lanzer, and H. A. del Portillo. 1997. Construction and characterization of a Plasmodium vivax genomic library in yeast artificial chromosomes. Genomics42:467-473.

10.4269/ajtmh.1997.57.495

Chin, W., P. G. Contacos, G. R. Coatney, and H. K. King. 1966. The evaluation of sulfonamides, alone or in combination with pyrimethamine, in the treatment of multi-resistant falciparum malaria. Am. J. Trop. Med. Hyg.15:823-829.

10.4269/ajtmh.1982.31.10

de Bruin, D., M. Lanzer, and J. V. Ravetch. 1992. Characterization of yeast artificial chromosomes from Plasmodium falciparum: construction of a stable, representative library and cloning of telomeric DNA fragments. Genomics14:332-339.

10.1016/0035-9203(79)90121-4

Eskandarian, A. A., H. Keshavarz, L. K. Basco, and F. Mahboudi. 2002. Do mutations in Plasmodium falciparum dihydropteroate synthase and dihydrofolate reductase confer resistance to sulfadoxine-pyrimethamine in Iran? Trans. R. Soc. Trop. Med. Hyg.96:96-98.

Findlay, G. M. 1951. Sulphonamides and sulphones, p. 377-403. In G. M. Findlay (ed.), Recent advances in chemotherapy, 3rd ed., vol. 2. J. and A. Churchill Ltd., London, United Kingdom.

Harinasuta, T., C. Viravan, and H. A. Reid. 1967. Sulphormethoxine in chloroquine-resistant falciparum malaria in Thailand. Lanceti:1117-1119.

10.4269/ajtmh.2003.69.247

Laing, A. B. G. 1968. Hospital and field trials of sulphormethoxine with pyrimethamine against Malaysian strains of Plasmodium falciparum and Plasmodium vivax. Med. J. Malaysia23:15-19.

10.1126/science.7725097

Martin, D. C., and J. D. Arnold. 1969. Trimethoprim and sulfalene therapy of Plasmodium vivax. J. Clin. Pharmacol.9:155-159.

Powell, R. D., R. L. DeGowin, and J. V. McNamara. 1967. Clinical experience with sulphadiazine and pyrimethamine in the treatment of persons experimentally infected with chloroquine-resistant Plasmodium falciparum. Ann. Trop. Med. Parasitol.61:396-408.

Rieckmann, K. H., G. J. Brewer, and R. D. Powell. 1968. Effects of diaphenylsulphone (dapsone) against Plasmodium vivax of South West Pacific origin. Trans. R. Soc. Trop. Med. Hyg.62:649-653.

10.1128/AAC.47.1.170-173.2003

10.1128/AAC.46.12.3947-3953.2002

10.1073/pnas.91.15.7149

10.1073/pnas.94.25.13944

10.1093/nar/16.16.8186

10.1093/emboj/17.14.3807

Walter, R. D., and E. Konigk. 1971. Plasmodium chabaudi: enzymatic synthesis of dihydropteroate and its inhibition by sulfonamides. Z. Tropenmed. Parasitol.22:256-259.

10.1016/S0166-6851(97)00114-X

World Health Organization. 1984. Advances in malaria chemotherapy. Report of a W. H. O. scientific group. Tech. Rep. Ser.711:63.

Thông tin
Thông tin xuất bản

Antimicrobial Agents and Chemotherapy

Tập 48 Số 6

2214-2222

Thông tin tác giả